Protara Therapeutics (TARA) Stock Forecast & Price Target

Compare

1,306 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TARA Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Protara

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TARA Stock 12 Month Forecast

Average Price Target

$24.83

▲(404.67% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Protara Therapeutics in the last 3 months. The average price target is $24.83 with a high forecast of $30.00 and a low forecast of $21.00. The average price target represents a 404.67% change from the last price of $4.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.33,7.227692307692308,9.125384615384615,11.023076923076923,12.920769230769231,14.81846153846154,16.716153846153844,18.613846153846154,20.511538461538464,22.409230769230767,24.306923076923077,26.204615384615387,28.10230769230769,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.33,6.83,8.33,9.83,11.33,12.83,14.33,15.83,17.33,18.83,20.33,21.83,23.33,{"y":24.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.33,6.535384615384615,7.740769230769231,8.946153846153846,10.151538461538461,11.356923076923076,12.56230769230769,13.767692307692307,14.973076923076922,16.178461538461537,17.38384615384615,18.589230769230767,19.794615384615383,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$24.83

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kelsey Goodwin

Piper Sandler

$24

Buy

387.80%

Upside

Reiterated

01/14/26

Piper Sandler Reaffirms Their Buy Rating on Protara Therapeutics (TARA)

Stacy Ku

TD Cowen

$50→$30

Buy

509.76%

Upside

Reiterated

01/07/26

TD Cowen Reaffirms Their Buy Rating on Protara Therapeutics (TARA)

Charles Zhu

LifeSci Capital

$26

Buy

428.46%

Upside

Reiterated

01/05/26

Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002

Andres Y. Maldonado

H.C. Wainwright

$23

Buy

367.48%

Upside

Reiterated

12/03/25

Protara's TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating

Soumit Roy

JonesTrading

$21

Buy

326.83%

Upside

Reiterated

12/03/25

Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial

Leland Gershell

Oppenheimer

$25

Buy

408.13%

Upside

Reiterated

11/20/25

Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)

George Farmer

Scotiabank

$12

Buy

143.90%

Upside

Reiterated

05/09/25

Protara Therapeutics (TARA) Gets a Buy from Scotiabank

Li Watsek

Cantor Fitzgerald

Buy

―

Initiated

03/14/25

Protara Therapeutics initiated with an Overweight at Cantor FitzgeraldProtara Therapeutics initiated with an Overweight at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kelsey Goodwin

Piper Sandler

$24

Buy

387.80%

Upside

Reiterated

01/14/26

Piper Sandler Reaffirms Their Buy Rating on Protara Therapeutics (TARA)

Stacy Ku

TD Cowen

$50→$30

Buy

509.76%

Upside

Reiterated

01/07/26

TD Cowen Reaffirms Their Buy Rating on Protara Therapeutics (TARA)

Charles Zhu

LifeSci Capital

$26

Buy

428.46%

Upside

Reiterated

01/05/26

Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002

Andres Y. Maldonado

H.C. Wainwright

$23

Buy

367.48%

Upside

Reiterated

12/03/25

Protara's TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating

Soumit Roy

JonesTrading

$21

Buy

326.83%

Upside

Reiterated

12/03/25

Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial

Leland Gershell

Oppenheimer

$25

Buy

408.13%

Upside

Reiterated

11/20/25

Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)

George Farmer

Scotiabank

$12

Buy

143.90%

Upside

Reiterated

05/09/25

Protara Therapeutics (TARA) Gets a Buy from Scotiabank

Li Watsek

Cantor Fitzgerald

Buy

―

Initiated

03/14/25

Protara Therapeutics initiated with an Overweight at Cantor FitzgeraldProtara Therapeutics initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protara Therapeutics

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+19.33%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +19.33% per trade.

1 Year

Andres Y. MaldonadoH.C. Wainwright

Success Rate

6/7 ratings generated profit

Average Return

+35.19%

reiterated a buy rating last month

Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +35.19% per trade.

2 Years

xxx

Success Rate

6/7 ratings generated profit

Average Return

+35.19%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +35.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TARA Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TARA has received 16 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. TARA average Analyst price target in the past 3 months is 24.83.

Each month's total comprises the sum of three months' worth of ratings.

TARA Financial Forecast

TARA Earnings Forecast

Next quarter’s earnings estimate for TARA is -$0.34 with a range of -$0.39 to -$0.29. The previous quarter’s EPS was -$0.31. TARA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TARA has Performed in-line its overall industry.

No data currently available

TARA Sales Forecast

Next quarter’s sales forecast for TARA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TARA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TARA has Performed in-line its overall industry.

TARA Stock Forecast FAQ

What is TARA’s average 12-month price target, according to analysts?

Based on analyst ratings, Protara Therapeutics’s 12-month average price target is 24.83.

What is TARA’s upside potential, based on the analysts’ average price target?

Protara Therapeutics has 404.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TARA a Buy, Sell or Hold?

Protara Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Protara Therapeutics’s price target?

The average price target for Protara Therapeutics is 24.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $21.00. The average price target represents 404.67% Increase from the current price of $4.92.

What do analysts say about Protara Therapeutics?

Protara Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of TARA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Protara Therapeutics (TARA) Stock Forecast & Price Target

TARA Analyst Ratings

TARA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protara Therapeutics

TARA Analyst Recommendation Trends

TARA Financial Forecast

TARA Earnings Forecast

TARA Sales Forecast

TARA Stock Forecast FAQ

Detailed List of Analyst Forecasts